173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer
Résumé
Background
Fusions in the neurotrophic tyrosine receptor kinase (NTRK) genes act as oncogenic drivers in many solid tumours, including secretory and non-secretory breast cancers. In the phase 2 STARTRK-2 clinical trial (NCT02568267), entrectinib (a TRK inhibitor with CNS activity) induced objective responses in 83.3% of patients (pts) with NTRK-fp breast cancer (2 complete responses [CR], 3 partial responses [PR], 1 missing; 31 Oct 2018 cutoff); we present updated data for this cohort.